ortho·cell
advancing tissue repair & regeneration

Orthocell's Ortho-ATI® shows 82% success rate

- **Orthocell's annual quality study shows 82% success rate** using Ortho-ATI® stem cell therapy for treatment of chronic tendon injuries
- **Annual quality study** captures patient feedback/outcomes for reduction of pain, functional improvement and overall satisfaction, in patients suffering from chronic tendon injuries
- **82% of patients responded as 'extremely satisfied'**, 'very satisfied' or 'satisfied' following treatment to shoulder, elbow, hip, knee and ankle tendons

Perth, Australia; 13th February 2019: Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce the results from its 2018 Annual Quality Study, which shows an 82% success rate using Ortho-ATI® stem cell therapy for the treatment of chronic tendon injuries.

Orthocell Managing Director, Paul Anderson, said: "We are delighted by these results which provide strong evidence that Ortho-ATI® is a breakthrough technology and significantly improves patients' lives. This novel therapy alleviates chronic pain, restores tendon structure and enables people to return to normal function at home and work. Ortho-ATI® has the potential to deliver significant socio-economic benefits, including improved individual productivity and reduced health care costs."

As part of Orthocell's commitment to its continuous delivery of high quality regenerative medicine products, the Company administers an Annual Quality Study to capture patient feedback following treatment of chronic tendon injuries with Orthocell's Ortho-ATI® stem cell therapy. The 2018 study indicated 82% of patients were 'satisfied' to 'extremely satisfied' with how Ortho-ATI® relieved symptoms (i.e. chronic pain) and improved ability to perform everyday activities at home and at work.

A sample of patient comments received as part of the study included:

Patient, Dean Allison: "Before having the treatment I underwent three lots of surgery and had pretty much accepted I would never be 100% again. I have experienced a 100% recovery, I am pain free, able to exercise and run without issue. I have been able to continue my job as a tactical flight officer".

Patient, Jane Naughton: *"Prior to Ortho-ATI® I had corticosteroid injections, blood/PRP injections and three separate surgeries and nothing worked. I could not walk 2kms without severe swelling and pain. I was in constant pain every night and for three years I woke at 3am in severe pain. Four weeks after the injection I walked 12km's, slept soundly and exercised without a limp. I can also run again".*

Chronic tendon pain is a highly prevalent condition. For example, tennis elbow (elbow pain) affects 1-3% of the general population. Ortho-ATI® is at the forefront of a large and growing market opportunity where the addressable market is estimated to be >US$7.7bn[1] and growing.

[1] US, Japanese, European and Australian markets

Annual quality study results

The Annual Quality Study is an important measure of patient satisfaction with the Ortho-ATI® stem cell treatment and compliments Orthocell's formal clinical studies that have been published in leading scientific journals, including the American Journal of Sports Medicine, reporting similar positive outcomes.

Forty seven (47) patients responded (treated outside of formal clinical studies undertaken by Orthocell) to the Annual Quality Study (29 females / 18 males; mean age of 57 years old). Summary results of the evaluation included:

- On average, patients were treated with Ortho-ATI® 23 months prior to completing the questionnaire
- 83% of patients were 'satisfied' to 'extremely satisfied 'with how Ortho-ATI® relieved symptoms such as pain
- 80% of patients were 'satisfied' to 'extremely satisfied' with how Ortho-ATI® improved their ability to perform activities of daily living at home and/or at work
- 82% of patients were 'satisfied' to 'extremely satisfied' overall with Ortho-ATI®
- Six (6) different anatomical locations (tendons) were treated including gluteal (43%), Elbow (19%), Shoulder (15%), Achilles (15%), Knee (4%) and Hamstring (4%) – refer to Figure 1.

Figure 1: Ortho-ATI® treatment sites 2018 Annual Quality Study



About Ortho-ATI®

Ortho-ATI® is a world leading breakthrough in regenerative medicine – a novel, cell therapy developed to treat chronic degenerative tendon injuries (tendinopathy / tendonitis). Tendinopathy places a significant financial burden on the public health care system which is expected to increase

as the population ages. Treating physicians and insurers are constantly seeking advances in new treatments that are safe, effective and cost efficient.

Ortho-ATI® addresses these demands by enabling the accelerated regeneration of injured tendons, directly addressing the underlying cause of injury, replenishing degenerative tissue with healthy mature tendon cells (known as tenocytes). The treatment allows patients to return to recreational activities, the workplace and competitive sports. Ortho-ATI® has extensive clinical validation with published clinical data up to 4.5 years post treatment in leading peer-reviewed journals (e.g. American Journal Sports Medicine), clearly demonstrating durability and efficacy as the leading tendon regeneration treatment.

Ortho-ATI® is available to patients in Australia, New Zealand, Singapore and Hong Kong.

For more information, please contact:

General & Investor enquiries

Paul Anderson
Orthocell Limited
Managing Director
P: +61 8 9360 2888
E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
Hales² Communications

P: +61 423 139 163
E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. Orthocell is moving forward with clinical studies designed to assist in the US (FDA) approval process and has completed its pre-IND meetings with the FDA. The Company's other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US and AUS.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter **@Orthocellltd** and Linkedin www.linkedin.com/company/orthocell-ltd